C4 Therapeutics Ownership | Who Owns C4 Therapeutics?
C4 Therapeutics Ownership Summary
C4 Therapeutics is owned by 93.99% institutional investors, 0.84% insiders, and 5.18% retail investors. Morgan stanley is the largest institutional shareholder, holding 7.03% of CCCC shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.01% of its assets in C4 Therapeutics shares.
CCCC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | C4 Therapeutics | 93.99% | 0.84% | 5.18% |
| Sector | Healthcare Stocks | 246.48% | 12.12% | -158.60% |
| Industry | Biotech Stocks | 384.82% | 11.76% | -296.58% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Morgan stanley | 8.87M | 7.03% | $41.41M |
| Blackrock | 4.55M | 6.61% | $21.03M |
| Ra capital management | 8.00M | 6.35% | $37.36M |
| Blackrock funding, inc. /de | 7.90M | 6.26% | $36.88M |
| Vanguard group | 4.38M | 6.04% | $8.37M |
| Lynx1 capital management lp | 7.33M | 5.81% | $34.22M |
| Bain capital life sciences investors | 7.17M | 5.69% | $33.49M |
| Jpmorgan chase | 4.75M | 3.77% | $20.65M |
| Vanguard capital management | 4.42M | 3.50% | $20.63M |
| Citadel advisors | 4.19M | 3.32% | $19.56M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Lynx1 capital management lp | 7.33M | 6.74% | $34.22M |
| Bain capital life sciences investors | 7.17M | 1.99% | $33.49M |
| Velan capital investment management lp | 570.00K | 1.62% | $2.66M |
| Silverarc capital management | 3.03M | 1.47% | $14.16M |
| Highvista strategies | 1.35M | 1.44% | $6.30M |
| Ikarian capital | 2.43M | 1.22% | $11.36M |
| Soleus capital management | 3.38M | 0.54% | $15.78M |
| Platinum investment management | 384.77K | 0.44% | $1.80M |
| Stempoint capital lp | 523.65K | 0.42% | $2.45M |
| Ra capital management | 8.00M | 0.32% | $37.36M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock funding, inc. /de | 7.90M | 0.00% | 5.85M |
| Blackrock | 4.55M | 0.00% | 3.65M |
| Ikarian capital | 2.43M | 1.22% | 2.43M |
| State street | 2.12M | 0.00% | 1.73M |
| Citadel advisors | 4.19M | 0.00% | 1.68M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Commodore capital lp | - | - | -3.41M |
| Samlyn capital | - | - | -3.02M |
| Patient square capital lp | - | - | -1.61M |
| Tcg crossover management | - | - | -1.28M |
| Renaissance | 1.19M | 0.01% | -1.27M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Ikarian capital | 2.43M | 1.22% | 2.43M | $11.36M |
| Highvista strategies | 1.35M | 1.44% | 1.35M | $6.30M |
| Sixth street partners management company | 781.06K | 0.00% | 781.06K | $3.65M |
| Boothbay fund management | 736.33K | 0.05% | 736.33K | $3.44M |
| Velan capital investment management lp | 570.00K | 1.62% | 570.00K | $2.66M |
Sold Out
| Holder | Change |
|---|---|
| Ifp advisors | -17.00 |
| Gradient investments | -25.00 |
| True wealth design | -31.00 |
| Coldstream capital management | -52.00 |
| Capital performance advisors llp | -54.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 157 | 22.66% | 118,493,656 | 40.24% | 93 | 2.09% | 106 | 43.24% | 27 | -10.00% |
| Mar 31, 2026 | 106 | -1.85% | 57,677,977 | -27.75% | 69 | 0.57% | 61 | -6.15% | 25 | 8.70% |
| Dec 31, 2025 | 18 | -82.52% | 4,929,202 | -90.62% | 6 | 0.12% | 9 | -82.35% | 6 | -82.86% |
| Sep 30, 2025 | 21 | -78.79% | 4,095,962 | -91.57% | 5 | 0.12% | 9 | -83.33% | 9 | -72.73% |
| Jun 30, 2025 | 100 | -13.04% | 54,689,267 | -14.68% | 77 | 0.90% | 55 | -19.12% | 33 | 17.86% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 2.14M | 3.01% | - |
| Vanguard Total Stock Mkt Idx Inv | 3.26M | 2.95% | 372.50K |
| Vanguard Morn Total Stk Mkt Idx Investor | 3.26M | 2.95% | 372.50K |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.26M | 2.65% | - |
| SPDR® S&P Biotech ETF | 1.57M | 2.22% | 22.34K |
| iShares Russell 2000 ETF | 2.60M | 1.98% | - |
| Wasatch Ultra Growth | 1.54M | 1.17% | -968.13K |
| Biotech Growth Ord | 1.10M | 1.00% | 889.80K |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.05M | 0.85% | 2.36K |
| Fidelity Small Cap Index | 1.11M | 0.85% | 3.79K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jan 16, 2026 | REYNO LEONARD | Chief Medical Officer | Sell | $22.20K |
| Feb 18, 2025 | Boyle Scott N | Chief Business Officer | Sell | $2.11K |
| Feb 14, 2025 | Boyle Scott N | Chief Business Officer | Sell | $1.54K |
| Feb 08, 2023 | Koppikar Utpal | - | Buy | $31.74K |
| Apr 12, 2022 | Hirsch Andrew | President & CEO | Buy | $84.00K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q4 | - | - |
| 2026 Q3 | - | - |
| 2026 Q2 | - | - |
| 2026 Q1 | - | 1 |
| 2025 Q4 | - | - |
CCCC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools